XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Total revenue $ 719 $ 273 $ 2,274 $ 273
Operating expenses:        
Research and development 11,092 12,605 22,420 24,136
General and administrative 14,900 13,397 25,497 25,952
Total operating expenses 25,992 26,002 47,917 50,088
Loss from operations (25,273) (25,729) (45,643) (49,815)
Other expense, net:        
Interest income 248 118 434 425
Interest expense (264) (702) (1,164) (1,388)
Benefit from research and development tax credit 28 381 56 586
Change in fair value of assets and liabilities, net (7,005) (30,600) (12,502) (31,800)
Gain on other investments 3,794 0 3,794 0
Change in fair value of digital assets, net 1,428 0 1,216 0
Loss on extinguishment of debt (1,317) 0 (1,317) 0
Foreign exchange gain (loss), net 1,460 122 1,916 (94)
Other expense, net (752) (667) (752) (672)
Total other expense, net (2,380) (31,348) (8,319) (32,943)
Net loss before income taxes (27,653) (57,077) (53,962) (82,758)
Provision for income taxes (93) (19) (249) (15)
Losses from investments in equity method investees, net of tax 0 (273) 0 (1,974)
Net loss (27,746) (57,369) (54,211) (84,747)
Net loss attributable to noncontrolling interests (17) (57) (51) (722)
Net loss attributable to ATAI Life Sciences N.V. stockholders $ (27,729) $ (57,312) $ (54,160) $ (84,025)
Net loss per share attributable to ATAI Life Sciences N.V. shareholders - basic $ (0.14) $ (0.36) $ (0.29) $ (0.53)
Net loss per share attributable to ATAI Life Sciences N.V. stockholders - diluted $ (0.14) $ (0.36) $ (0.29) $ (0.53)
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V.Stockholders - basic 196,563,699 160,387,701 186,473,494 159,643,518
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - diluted 196,563,699 160,387,701 186,473,494 159,643,518
License [Member]        
Total revenue $ 0 $ 273 $ 202 $ 273
Research and development services revenue [Member]        
Total revenue $ 719 $ 0 $ 2,072 $ 0